FOXO1 and nasopharyngeal carcinoma: This study provided an experimental basis for anti-tumor therapy by targeting COX-2.100 FOXO1 suppresses the expression of MYH9 by inhibiting the PI3K/Akt/c-Myc/p53/miR-133a-3p pathway, thereby inhibiting the stem cell characteristics, metastasis and increasing cisplatin sensitivity of NPC cells.71 B-cell-specific Moloney murine leukemia virus insertion site 1 (Bmi-1) can improve the proliferation, migration, and invasion ability of NPC cells by inhibiting the p16INK4a-p14ARF-p53 pathway.